Ozempic (Semaglutide) Once-Weekly Injection
Ozempic is a prescription once-weekly subcutaneous injection containing semaglutide, a GLP-1 receptor agonist used in adults with type 2 diabetes to improve glycaemic control and to reduce major cardiovascular events.
- Active ingredients
- Semaglutide
- Manufacturer
- Novo Nordisk
- Dosage forms
- pre-filled pen
- Available dosages
- 0.25mg, 0.5mg, 1mg, 2mg
- Category
- Diabetes Treatment
What is it?
Ozempic is the brand name for semaglutide as a once-weekly subcutaneous injection developed by Novo Nordisk and approved by the United States Food and Drug Administration in 2017 and by the European Medicines Agency in 2018. It is supplied as a pre-filled multi-dose pen and is intended exclusively for adult use under medical prescription. Ozempic is not the same brand as the higher-dose semaglutide product approved for chronic weight management.
Active ingredients
Each pen contains semaglutide as the sole active ingredient. Available pen strengths deliver 0.25mg, 0.5mg, 1mg or 2mg per weekly injection. Semaglutide is a long-acting GLP-1 receptor agonist with reversible albumin binding through a fatty diacid linker, which extends its half-life to about a week. The molecule mimics the action of endogenous glucagon-like peptide 1 on the pancreatic, central and gastrointestinal pathways.
Forms and dosages
Ozempic is administered once weekly by subcutaneous injection into the abdomen, thigh or upper arm. According to the prescribing information, treatment starts at 0.25mg per week as a tolerability dose for four weeks, then increases to 0.5mg per week, with possible further escalation to 1mg or 2mg depending on glycaemic response and tolerability. Injection day can be changed if the new day is at least 48 hours from the previous one. Pens must be stored refrigerated before first use.
Indications
The medication is indicated in adults with type 2 diabetes mellitus, alone or in combination with other antidiabetic agents, to improve glycaemic control. In several markets a second indication is the reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease. Ozempic is not indicated for type 1 diabetes, diabetic ketoacidosis, paediatric use under specific local labelling or for cosmetic weight loss in people without a recognised indication.
How it works
After subcutaneous injection, semaglutide is absorbed slowly and binds to the GLP-1 receptor in pancreatic beta cells, alpha cells, central nervous system and gut. Receptor activation enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying and reduces appetite through hypothalamic centres. The combined effect lowers fasting and post-prandial glucose without intrinsic hypoglycaemia risk and produces moderate weight reduction. Steady state is reached after about four to five weeks of weekly dosing.
Frequently asked questions
How is Ozempic different from Wegovy? ▾
Both contain the same active molecule, semaglutide, but at different maintenance doses and for different indications. Ozempic is approved for type 2 diabetes at maintenance doses of 0.5 to 2mg weekly, while Wegovy is approved for chronic weight management at a target maintenance dose of 2.4mg weekly in adults with obesity or with overweight and weight-related comorbidity. According to the prescribing information, the two products are not interchangeable without medical assessment.
How long does it take for Ozempic to work? ▾
Glycaemic effects begin within the first weeks of treatment and continue to improve as the dose is increased and steady state is reached, typically after four to five weeks of weekly dosing. Weight reduction is gradual, usually progressing over months. According to the prescribing information, response should be reassessed by a clinician at regular intervals, with HbA1c, weight and tolerability guiding further dose adjustments.
Does Ozempic cause hypoglycaemia? ▾
Ozempic enhances insulin secretion only when glucose is elevated, so it carries a low intrinsic risk of hypoglycaemia in monotherapy. Hypoglycaemia is more likely when Ozempic is combined with insulin or sulfonylureas; in this situation the prescribing information advises that the dose of these companion agents may need to be reduced, under medical supervision, when Ozempic is started or escalated.
Can Ozempic be used for weight loss? ▾
Ozempic is not approved as a weight management product. The semaglutide molecule is approved at higher doses under a different brand name for chronic weight management in adults with obesity or with overweight and at least one weight-related comorbidity. According to the prescribing information, prescribing Ozempic outside its approved indication should be discussed with a qualified clinician, who will weigh expected benefit against risk.
What are the main contraindications for Ozempic? ▾
Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 and known hypersensitivity to semaglutide are formal contraindications. Caution is required in patients with previous pancreatitis, severe gastroparesis, diabetic retinopathy or active gallbladder disease, and during pregnancy and breastfeeding. According to the prescribing information, the medical history and current medication list must be reviewed by a clinician before any prescription.
Related medications
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.